Clinical Observations
Treatment of Myocardial
Ischemia with CardioPhase

Wang Wenmao, Liang Lide, Du Xiaoyang
The First Affiliated Hospital School of Medicine, Xi’an Jiaotong University, Xi’an 710061 China

Abstract: Animal experiments have demonstrated that CardioPhase protects the myocardium and improves myocardial metabolism while preventing myocardial damage. The aim of our study was to evaluate the clinical effectiveness of CardioPhase in treating patients with organic heart disease caused by myocardial ischemia.

The study compared results after a four-week course of treatment involving patients with organic heart disease caused by myocardial ischemia. 52 patients were treated with CardioPhase and 15 with the beta-blocker drug propranolol.

CardioPhase was found to improve clinical symptoms in 87.07 percent of patients. Additionally CardioPhase improved electrocardiogram [ECG] scores in 41.93 percent of subjects. By comparison, of the patients receiving propranolol 68.57 percent demonstrated improvement of symptoms and 39.99 percent had improved ECG scores.

Study results showed CardioPhase is effective in treating myocardial ischemia and is superior to propranalol as demonstrated by improved symptoms and ECG readings.

Materials and Methods

The CardioPhase treatment group was composed of 52 patients with myocardial ischemia from various types of heart disease. Subjects included 33 male and 19 females, with ages ranging from 19 to 74 years of age, with an average age of 49.8 years. All subjects were diagnosed prior to the study with coronary artery disease, including 21 cases of previous myocardial infarction, 6 cases of acute myocardial infarction, 3 cases of hypertensive heart disease, 10 cases of myocarditis and one case of rheumatic heart disease.

The control group consisted of 15 cases of myocardial ischemia treated by propranolol, 7 men and 8 women. The youngest subject was 13 and the oldest 72 with an average age of 43.8. Of the cases 8 had coronary artery disease, 5 cardiomyopathy and 2 rheumatic heart disease.

Subjects in the CardioPhase group received 20ml of CardioPhase three times daily for four weeks. Patients in the control group received 5 to 10 mg propranolol, three times daily for four weeks. Each patient was given an ECG prior to the study and again one each week during the course of the study. Additionally a sample group of patients from each group was evaluated for levels of myocardial enzymes before and at the end of the trial.

Evaluation of the effectiveness of treatment was based on the following criteria

Effective defined as alleviation of symptoms and improvement in ECG readings showing normal S-T segments and T waves.

Improved defined as improvement of symptoms but not alleviation accompanied by improvement or normalization in S-T segments or T waves.

Ineffective defined as minor or no improvement in symptom, and no change in S-T segments or T waves.

Results
The total effective rate of CardioPhase for improving symptoms was 89.07% (Table 1). 9.68% of CardioPhase patients showed excellent effect in ECG measurements, while 32.25% were effective and 58.07% were ineffective for a total effective power of 41.93%. The effective power of propranolol in improving symptom was 68.57% (Table 2). in ECG measurements the propranolol patients had 13.33% measuring as excellent effect, 26.66% were effective, 60.01% were ineffective and the total effective power was 39.99%.

Discussion
Myocardial ischemia and subsequent myocardial damage caused by coronary artery disease and other heart disorders are common clinical presentations. Standard treatments to reduce myocardial ischemia and damage have included vasodilating agents, Beta-blockers, calcium blockers and Traditional Chinese Medicine formulations that promote blood flow.

Animal experiments had demonstrated that CardioPhase can treat myocardial ischemia by improving myocardial microcirculation, promoting myocardial metabolism, enhancing serum levels of glutathione, and stimulating oxidation-reduction to reduce free radical damage. The experiments showed that CardioPhase can protect the myocardium and promote its resistance to damage.

Propranolol exerts myocardial benefits by slowing the heart rate, reducing myocardial contractility and reducing the oxygen consumption requirements of heart tissue.

Clinical observations in our study indicate that CardioPhase can be effective in treating myocardial ischemia and myocardial damage from many types of heart disease, including myocarditis and coronary artery disease. CardioPhase was shown to be superior to propranolol in relieving clinical symptoms of heart diseases and improving ECG readings. CardioPhase was also determined be both convenient to use and free of side effects.